Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
$2.77
+2.2%
$2.32
$1.47
$17.31
$67.67MN/A225,397 shs29,248 shs
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
$3.53
+0.9%
$3.51
$2.45
$4.14
$280.14M0.25385,478 shs233,288 shs
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
$9.54
-2.7%
$9.79
$2.20
$12.78
$261.30M-0.58203,752 shs24,781 shs
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
$7.35
+2.4%
$8.72
$1.73
$11.41
$225.42M3.371.10 million shs380,744 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
-2.87%+1.50%+6.27%+36.87%-73.14%
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
+0.29%0.00%+2.04%+22.81%-7.89%
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
+1.07%-0.35%+3.95%+12.60%+117.03%
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
+3.91%-25.05%-18.69%+110.56%+136.96%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
2.7912 of 5 stars
3.50.00.00.01.52.51.3
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
1.7722 of 5 stars
3.30.00.00.00.62.51.3
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
3.3198 of 5 stars
3.45.00.00.02.02.50.6
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
3.3684 of 5 stars
3.54.00.00.03.33.30.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
3.00
Buy$17.00513.72% Upside
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
2.50
Moderate Buy$6.0069.97% Upside
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
2.80
Moderate Buy$14.7554.61% Upside
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
3.00
Buy$25.67249.21% Upside

Current Analyst Ratings Breakdown

Latest ARTV, DBVT, AVIR, and SGMT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/11/2025
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$28.00
8/7/2025
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$29.00
7/24/2025
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$28.00
6/26/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/26/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$21.00
6/11/2025
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeBuy$12.00
6/6/2025
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$15.00 ➝ $27.00
5/29/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeSell$7.25
5/27/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
5/27/2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$15.00 ➝ $21.00
(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
$250K270.68N/AN/A$6.10 per share0.45
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/AN/AN/AN/A$4.59 per shareN/A
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
$4.15M62.96N/AN/A$3.15 per share3.03
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
$2M112.71N/AN/A$4.24 per share1.73
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
-$65.37MN/A0.00N/AN/AN/A-42.60%-37.76%N/A
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-$168.38M-$1.61N/AN/AN/AN/A-32.55%-30.47%11/6/2025 (Estimated)
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
-$113.92M-$4.77N/AN/AN/A-3,220.49%-287.15%-138.83%11/5/2025 (Estimated)
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
-$45.57M-$1.83N/AN/AN/AN/A-39.88%-38.40%N/A

Latest ARTV, DBVT, AVIR, and SGMT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
-$0.52-$0.32+$0.20-$0.32N/AN/A
8/7/2025Q2 2025
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-$0.46-$0.44+$0.02-$0.44N/AN/A
8/6/2025Q2 2025
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
-$0.84-$0.87-$0.03-$0.87N/AN/A
7/29/2025Q2 2025
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
-$0.21-$1.55-$1.34-$1.55$0.64 million$1.74 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
N/AN/AN/AN/AN/A
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/AN/AN/AN/AN/A
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
N/AN/AN/AN/AN/A
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
N/A
13.84
13.84
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/A
19.17
19.17
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
N/A
2.45
2.45
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
N/A
17.55
17.55

Institutional Ownership

CompanyInstitutional Ownership
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
N/A
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
86.67%
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
71.74%
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
87.86%

Insider Ownership

CompanyInsider Ownership
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
21.40%
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
18.10%
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
1.44%
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
14.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Artiva Biotherapeutics, Inc. stock logo
ARTV
Artiva Biotherapeutics
8124.43 million19.20 millionN/A
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
7079.36 million64.99 millionOptionable
DBV Technologies S.A. stock logo
DBVT
DBV Technologies
8027.39 million27.00 millionOptionable
Sagimet Biosciences Inc. stock logo
SGMT
Sagimet Biosciences
830.67 million26.17 millionOptionable

Recent News About These Companies

What is Wedbush's Estimate for SGMT Q2 Earnings?
Q2 Earnings Estimate for SGMT Issued By Wedbush
Sagimet Biosciences Tops Q2 EPS Forecast
Sagimet Biosciences (SGMT) to Release Earnings on Wednesday
What is HC Wainwright's Estimate for SGMT Q2 Earnings?
Sagimet Biosciences (NASDAQ:SGMT) Upgraded at HC Wainwright

New MarketBeat Followers Over Time

Media Sentiment Over Time

Artiva Biotherapeutics stock logo

Artiva Biotherapeutics NASDAQ:ARTV

$2.77 +0.06 (+2.21%)
Closing price 04:00 PM Eastern
Extended Trading
$2.79 +0.02 (+0.72%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Atea Pharmaceuticals stock logo

Atea Pharmaceuticals NASDAQ:AVIR

$3.53 +0.03 (+0.86%)
Closing price 04:00 PM Eastern
Extended Trading
$3.52 -0.01 (-0.28%)
As of 04:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

DBV Technologies stock logo

DBV Technologies NASDAQ:DBVT

$9.87 +0.07 (+0.71%)
As of 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.

Sagimet Biosciences stock logo

Sagimet Biosciences NASDAQ:SGMT

$7.35 +0.17 (+2.37%)
Closing price 04:00 PM Eastern
Extended Trading
$7.22 -0.13 (-1.70%)
As of 07:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.